Crispr Therapeutics
Zug, Switzerland · Biotechnology, Genetics, Healthcare
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Zug, Switzerland
- Employees
- 344
- Industries
- Biotechnology, Genetics, Healthcare
- Status
- Public (CRSP)
- Website
- crisprtx.com
- Company page
Recent activity at Crispr Therapeutics
- : Crispr Therapeutics names Sivakesava Sakhamuri Chief Technical Officer
- : CRISPR Therapeutics Appoints Andrew J. Silver as Chief Financial Officer
- : SEC 8-K (5.02): CRISPR Therapeutics AG announced the appointment of Andrew J. Silver as Chief Financial Officer, effective immediately on October 19, 2026. Previously serving as Senior Vice President of Finance since January 2025, Mr. Silver has an extensive background in finance and accounting, having spent over 10 years at Ernst & Young LLP. His new role comes with an annual salary of $515,000, a target annual bonus of 45%, and a one-time grant of 25,000 restricted stock units that will vest in two years, contingent upon continued service. The Employment Agreement includes provisions for termination with a six-month notice period if he is let go without cause or resigns for good reason.
About Crispr Therapeutics: questions and answers
What does Crispr Therapeutics do?
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas
Where is Crispr Therapeutics headquartered?
Crispr Therapeutics is headquartered in Zug, Switzerland.
How many employees does Crispr Therapeutics have?
Crispr Therapeutics has about 344 employees.
What is the latest news on Crispr Therapeutics?
On Nov 03, 2026, Crispr Therapeutics names Sivakesava Sakhamuri Chief Technical Officer
Is Crispr Therapeutics a public company?
Yes. Crispr Therapeutics is publicly traded under the ticker CRSP.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy